

AD_____

Award Number: W81XWH-04-1-0344

TITLE: Targeting of the nuclear receptor coactivator isoform $\Delta 3AIB$ in breast cancer

PRINCIPAL INVESTIGATOR: Aparna Mani

CONTRACTING ORGANIZATION: Georgetown University
Washington, DC 20057-1411

REPORT DATE: March 2006

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) March 2006		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 23 Feb 05 – 22 Feb 06	
Targeting of the nuclear receptor coactivator isoform Δ 3AIB in breast cancer				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0344	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Aparna Mani E-mail: am2@geogetown.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Georgetown University Washington, DC 20057-1411				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT AIB1 which stands for "Amplified in Breast cancer", codes for a protein that is a member of the steroid receptor coactivator (SRC) family. AIB1 is amplified in approximately 5-10% of breast cancers and the mRNA and protein over expressed in >30% of breast cancers. AIB1 interacts with a super family of ligand activated nuclear receptors to potentiate transcriptional activity leading to upregulation of downstream target gene expression. An important finding was that an isoform of AIB1 (Δ 3AIB1) is a significantly more effective coactivator of the estrogen receptor than AIB1 and is highly over expressed in human breast cancer. Prior work in our lab showed that the downregulation of overall levels of AIB1 plus Δ 3AIB1, using a regulatable AIB1 directed ribozyme, resulted in reduced tumor growth in vivo. Overall, these data indicate a major role for AIB1 and its isoform Δ 3AIB1 in breast cancer development and growth. However the relative roles of AIB1 versus the more highly active Δ 3AIB1 in phenotypic changes in the breast has not been determined. In this investigation, we are developing a method to use siRNA directed at Δ 3AIB1 in order investigate its role in breast cancer and as a possible future therapeutic approach to breast cancer.					
15. Subject Terms (keywords previously assigned to proposal abstract or terms which apply to this award) No keywords provided					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	12	19b. TELEPHONE NUMBER (include area code)

Table of Contents

Cover.....	page 1
SF 298.....	page 2
Introduction.....	page 4
Body.....	page 5
Key Research Accomplishments.....	page 9
Reportable Outcomes.....	page 10
Conclusions.....	page 11
References.....	page 12

INTRODUCTION

Of particular interest to breast cancer was the discovery that an area of chromosome 20q, known to be frequently amplified in breast cancer, harbored the gene for AIB1. AIB1 which stands for " **A**mplified in **B**reast cancer" codes for a protein which is a member of the steroid receptor coactivator (SRC) family. AIB1 is amplified in approximately 5-10% of breast cancers and the mRNA and protein overexpressed in >30% of breast cancers. AIB1 interacts with a superfamily of ligand activated nuclear receptors including the estrogen receptor (ER) and progesterone receptor (PR) to potentiate transcriptional activity leading to upregulation of downstream target gene expression. An important finding was that an isoform of AIB1 (Δ 3AIB1) is a significantly more effective coactivator of the estrogen receptor than AIB1 and is highly overexpressed in human breast cancer. Prior work in our lab showed that the downregulation of overall levels of AIB1 plus Δ 3AIB1, using a regulatable AIB1 directed ribozyme, resulted in reduced tumor growth *in vivo*. Overall, these data indicate a major role for AIB1 and its isoform Δ 3AIB1 in breast cancer development and growth. However the relative roles of AIB1 versus the more highly active Δ 3AIB1 in phenotypic changes in the breast has not been determined. Specifically, the research done with the funding of this grant will examine and compare the effects of selective reduction in the gene expression of isoform Δ 3AIB1 by siRNA versus the phenotypic responses to siRNA directed at both AIB1/ Δ 3AIB1. Ultimately, the information from this study will be used as a basis for the development of AIB1 and Δ 3AIB1 directed siRNA as a potential therapy in humans.

BODY

Task 1: Design small interfering siRNA molecules that specifically target the nuclear receptor coactivator isoform $\Delta 3$ AIB1.

In addition to developing siRNAs to target the nuclear receptor coactivator isoform $\Delta 3$ AIB1, we are now in the process of designing and developing a lentiviral plasmid system to express short-hairpin RNAs to target AIB1 and $\Delta 3$ AIB1. We tried targeting AIB1 with five different short-hairp RNAs as listed below. (Figure 1) Currently, we have successfully developed a lentiviral system to target and AIB1 with three of our of five of the short-hairpin RNAs we tried. Our results showed that we are able to knockdown protein levels of AIB1 in the human breast cancer cell line MDA-MB-231. (Figure 2) The lentiviral system was also able to knockdown protein levels of AIB1 in other breast cancer cell lines including MCF-7 breast cancer cell line. This lentiviral system will serve as a framework to develop a lentiviral expressed short hairpin RNAs to target the $\Delta 3$ AIB1 isoform.

NCOA3 (AIB1) shRNA-lentivirus

TRCN0000019699

CCGGGCCGCATTACTACAGGAGAACTCGAGTTTCTCCTGTAGTAATGCGGCTTTTT

Clone ID: NM_006534.2-957s1c1

Accession Number(s): NM_181659.1, NM_006534.2

TRCN0000019700

CCGGCCATACATTTAATTGCCGTATCTCGAGATACGGCAATTAAATGTATGGTTTT

Clone ID: NM_006534.2-781s1c1

TRCN0000019701

CCGGCCTCCGCAACAGTTTCCATATCTCGAGATATGGAACTGTTGCGGAGGTTTT

Clone ID: NM_006534.2-4106s1c1

TRCN0000019702

CCGGCCTCTACATCTGGAGGAGTATCTCGAGATACTCCTCCAGATGTAGAGGTTTT

Clone ID: NM_006534.2-2187s1c1

TRCN0000019703

CCGGGCAGTCTATTCGTCCTCCATACTCGAGTATGGAGGACGAATAGACTGCTTTT

Clone ID: NM_006534.2-2740s1c1

Figure 1: We obtained the above listed five sequences for short-hairpin RNAs to knockdown AIB1 protein levels from the RNAi Consortium. This database was developed by MIT and contains a lentiviral plasmid library that expresses short-hairpin RNAs to target 15,000 human genes (http://www.borad.mit.edu/genome_bio/trc/).




Figure 2: HEK293T cells were transfected with the individual shRNA vector, packaging vector, and envelope vector. Twenty four hours after plating, the cells were replaced with fresh media. This media or supernatant was then collected after twenty-four hours, filtered and then added to MDA-MB 231 cells. After twenty four hours, the MDA-MB 231 cells were harvested, a protein lysate was made and analyzed by western blot for AIB1 expression. Action was used as a loading control.

Task 2: To determine if siRNA reduction of cellular levels of AIB1 of $\Delta 3$ AIB1 can change the phenotype of breast cancer cell lines. (Please see appended reprint.)

During ongoing studies of $\Delta 3$ AIB1 in breast cancer, we have recently observed that AIB1 is proteasomally degraded in response to serum withdrawal and high cell density conditions in several immortalized cell lines. We have recently submitted a manuscript discussing these novel findings. Interestingly, in contrast to this phenomenon, **we have found that the $\Delta 3$ AIB1 isoform is resistant to degradation in high cell density conditions.** (Figure 3) It would be interesting to target $\Delta 3$ AIB1 by shRNA developed under Task 1 to see if can knockdown protein levels in high cell density conditions. This result may hold important implications for the study we plan to do in this task where we will specifically target $\Delta 3$ AIB1 isoform.




Figure 3: HEK293T cells were plated at 2.75×10^6 cells per 100mm tissue culture plate. Cells were transfected with wildtype AIB1, $\Delta 3$ AIB1 isoform, or AIB1 serine phosphorylation mutants 24 hours after plating. Cells were harvested with RIPA buffer 24 hours after transfection and analyzed by Western blot for AIB1 expression. Results are representative of 2 separate experiments.

Task 3: To determine if $\Delta 3AIB1$ siRNA is effective *in vivo*.

We have not formally begun this task since we are awaiting the development of the $\Delta 3AIB1$ siRNA. The recent observation that we made showing that the $\Delta 3AIB1$ isoform is resistant to density dependent proteasomal degradation to which the wild-type AIB1 is susceptible is an intriguing and novel finding. We speculate that resistance to degradation displayed by the $\Delta 3AIB1$ isoform in a high cell density condition might provide a mechanistic explanation for the finding by Reiter et al that the isoform's ability to promote transcription mediated by the estrogen or progesterone receptors was significantly greater than that of the full-length protein.¹

KEY RESEARCH ACCOMPLISHMENTS

Development of a lentiviral plasmid system to express short-haripin RNAs to target AIB1.

REPORTABLE OUTCOMES

“E6-AP mediates regulated proteasomal degradation of the nuclear receptor coactivator AIB1/SRC-3 in immortalized cells.” **Aparna Mani**, Annabell S Oh, Emma T Bowden, Tyler Lahusen, Kevin L Lorick, Allan M Weissman, Richard Schlegel, Anton Wellstein, and Anna T. Riegel”, manuscript submitted to *Cancer Research*.

CONCLUSIONS

The work done to date as outlined in this report illustrates that it is possible to specifically target AIB1 using a short-haripin RNAs expressed through a lentiviral system. This gives us an initial framework from which we can design and develop short-haripin RNAs to specifically target $\Delta 3$ AIB1. In addition, we plan to continue studies on the intriguing finding the isoform $\Delta 3$ AIB1 is resistant to proteasomal degradation compared to wild-type AIB1.

REFERENCES

1. Reiter et al. 2001, *J Biol Chem.* V276:39736-41.